Literature DB >> 32989445

An overview of the medical-physics-related verification system for radiotherapy multicenter clinical trials by the Medical Physics Working Group in the Japan Clinical Oncology Group-Radiation Therapy Study Group.

Teiji Nishio1,2, Mitsuhiro Nakamura3,2, Hiroyuki Okamoto4,2, Satoshi Kito5,6,3,2, Toshiyuki Minemura7,2, Shuichi Ozawa8,9,2, Yu Kumazaki10,2, Masayori Ishikawa11,2, Naoki Tohyama12,2, Masahiko Kurooka13,2, Takeo Nakashima14,2, Hidetoshi Shimizu15,2, Ryusuke Suzuki16,2, Satoshi Ishikura17,18,19, Yasumasa Nishimura20,19.   

Abstract

The Japan Clinical Oncology Group-Radiation Therapy Study Group (JCOG-RTSG) has initiated several multicenter clinical trials for high-precision radiotherapy, which are presently ongoing. When conducting multi-center clinical trials, a large difference in physical quantities, such as the absolute doses to the target and the organ at risk, as well as the irradiation localization accuracy, affects the treatment outcome. Therefore, the differences in the various physical quantities used in different institutions must be within an acceptable range for conducting multicenter clinical trials, and this must be verified with medical physics consideration. In 2011, Japan's first Medical Physics Working Group (MPWG) in the JCOG-RTSG was established to perform this medical-physics-related verification for multicenter clinical trials. We have developed an auditing method to verify the accuracy of the absolute dose and the irradiation localization. Subsequently, we credentialed the participating institutions in the JCOG multicenter clinical trials that were using stereotactic body radiotherapy (SBRT) for lungs, intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT) for several disease sites, and proton beam therapy (PT) for the liver. From the verification results, accuracies of the absolute dose and the irradiation localization among the participating institutions of the multicenter clinical trial were assured, and the JCOG clinical trials could be initiated.
© The Author(s) 2020. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Radiation Oncology.

Entities:  

Keywords:  credentialing; dosimetry audit; irradiation localization audit; radiotherapy clinical trial

Year:  2020        PMID: 32989445      PMCID: PMC7674673          DOI: 10.1093/jrr/rraa089

Source DB:  PubMed          Journal:  J Radiat Res        ISSN: 0449-3060            Impact factor:   2.724


  33 in total

1.  Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02.

Authors:  Lester J Peters; Brian O'Sullivan; Jordi Giralt; Thomas J Fitzgerald; Andy Trotti; Jacques Bernier; Jean Bourhis; Kally Yuen; Richard Fisher; Danny Rischin
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

2.  Liver phantom design and dosimetric verification in participating institutions for a proton beam therapy in patients with resectable hepatocellular carcinoma: Japan Clinical Oncology Group trial (JCOG1315C).

Authors:  Teiji Nishio; Hidenobu Tachibana; Yuki Kase; Kenji Hotta; Mitsuhiro Nakamura; Masaya Tamura; Toshiyuki Terunuma; Toshiyuki Toshito; Haruo Yamashita; Satoshi Ishikura; Hiroshi Fuji; Tetsuo Akimoto; Yasumasa Nishimura
Journal:  Radiother Oncol       Date:  2019-06-29       Impact factor: 6.280

3.  Virtual EPID standard phantom audit (VESPA) for remote IMRT and VMAT credentialing.

Authors:  Narges Miri; Joerg Lehmann; Kimberley Legge; Philip Vial; Peter B Greer
Journal:  Phys Med Biol       Date:  2017-03-01       Impact factor: 3.609

Review 4.  Quality assurance for prospective EORTC radiation oncology trials: the challenges of advanced technology in a multicenter international setting.

Authors:  Damien C Weber; Philip M P Poortmans; Coen W Hurkmans; Edwin Aird; Akos Gulyban; Alysa Fairchild
Journal:  Radiother Oncol       Date:  2011-06-29       Impact factor: 6.280

5.  A randomized Phase III trial of comparing two dose-fractionations stereotactic body radiotherapy (SBRT) for medically inoperable Stage IA non-small cell lung cancer or small lung lesions clinically diagnosed as primary lung cancer: Japan Clinical Oncology Group Study JCOG1408 (J-SBRT trial).

Authors:  Tomoki Kimura; Yasushi Nagata; Junko Eba; Shuichi Ozawa; Satoshi Ishikura; Taro Shibata; Yoshinori Ito; Masahiro Hiraoka; Yasumasa Nishimura
Journal:  Jpn J Clin Oncol       Date:  2017-01-09       Impact factor: 3.019

6.  Dosimetric verification in participating institutions in a stereotactic body radiotherapy trial for stage I non-small cell lung cancer: Japan clinical oncology group trial (JCOG0403).

Authors:  Teiji Nishio; Etsuo Kunieda; Hiroki Shirato; Satoshi Ishikura; Hiroshi Onishi; Kunihiko Tateoka; Masahiro Hiraoka; Yuichirou Narita; Masataka Ikeda; Tomonori Goka
Journal:  Phys Med Biol       Date:  2006-10-06       Impact factor: 3.609

7.  Positional uncertainty of vaginal cuff and feasibility of implementing portable bladder scanner in postoperative cervical cancer patients.

Authors:  Hiroyuki Okamoto; Naoya Murakami; C Claudia Carvajal; Yuki Miura; Akihisa Wakita; Satoshi Nakamura; Shie Nishioka; Kotaro Iijima; Koji Inaba; Yoshinori Ito; Tomoyasu Kato; Takafumi Toita; Jun Itami
Journal:  Phys Med       Date:  2017-12-01       Impact factor: 2.685

8.  A phase II study of adaptive two-step intensity-modulated radiation therapy (IMRT) with chemotherapy for loco-regionally advanced nasopharyngeal cancer (JCOG1015).

Authors:  Yasumasa Nishimura; Satoshi Ishikura; Taro Shibata; Takeshi Kodaira; Yoshinori Ito; Kazuhiko Tsuchiya; Yuji Murakami; Jun-Ichi Saitoh; Tetsuo Akimoto; Kensei Nakata; Michio Yoshimura; Teruki Teshima; Takashi Toshiyasu; Yosuke Ota; Kazuki Ishikawa; Hidetoshi Shimizu; Toshiyuki Minemura; Kenichi Nakamura; Masahiro Hiraoka
Journal:  Int J Clin Oncol       Date:  2020-03-27       Impact factor: 3.402

9.  A primary analysis of a multicenter, prospective, single-arm, confirmatory trial of hypofractionated whole breast irradiation after breast-conserving surgery in Japan: JCOG0906.

Authors:  Miwako Nozaki; Yoshikazu Kagami; Taro Shibata; Kenichi Nakamura; Yoshinori Ito; Yasumasa Nishimura; Yoshifumi Kawaguchi; Yoshihiro Saito; Yasushi Nagata; Yasuo Matsumoto; Tetsuo Akimoto; Masahiro Hiraoka
Journal:  Jpn J Clin Oncol       Date:  2019-01-01       Impact factor: 3.019

10.  The prolonged interval between induction chemotherapy and radiotherapy is associated with poor prognosis in patients with nasopharyngeal carcinoma.

Authors:  Liang Peng; Jin-Qi Liu; Cheng Xu; Xiao-Dan Huang; Ling-Long Tang; Yu-Pei Chen; Ying Sun; Jun Ma
Journal:  Radiat Oncol       Date:  2019-01-17       Impact factor: 3.481

View more
  1 in total

1.  The Value of On-Site Proton Audits.

Authors:  Paige A Taylor; Jessica Lowenstein; David Followill; Stephen F Kry
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-11-13       Impact factor: 7.038

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.